Overview

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and feasibility of collecting hematopoietic stem cells (HSC) in participants with RUNX1-FPD.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
RUNX1 Foundation
Treatments:
Biosimilar Pharmaceuticals
Blood Component Removal
Filgrastim
Granulocyte Colony-Stimulating Factor
pegfilgrastim
plerixafor